Moreover, a phase IIa study LUC2001 (NCT02699606) demonstrated an ORR of 50% in patients with advanced cholangiocarcinoma exhibiting FGFR alterations (FGFR2 fusions n = 8, FGFR2 mutations n = 3, FGFR3 fusion n = 1, FGFR3 mutations n = 2) treated with erdafitinib, who progressed on systemic treatment [46]. This evidence concerns the gene FGFR3 and cholangiocarcinoma.